BioSpace News Archive

Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on ophthalmology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for cyclosporine topical ophthalmic emulsion, 0.1% for the treatment of se

Foldax® , Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted approval to expand the U.S. clinical study of the Tria™ surgical aortic heart valve. This next stage of enrollment is expected to begin within the next month. “We are excited to expand enrollment in this U.S. clinical study to gain additional clinical experience with the Tria valve,” stated Frank Shannon, MD, Chief of Cardiov

Sunovion Pharmaceuticals Inc. announced that the company is marking ten years since it was established in October 2010.

PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar third quarter 2020 financial results by press release on Monday, November 9, 2020 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on November 9, 2020 at 8:00 a.m. Eastern Time. The conference call can be accessed by calling 1-888-599-8688 (U.S. and Canada) or +44 (0)330 33

Meeting outcome confirms the Company’s pathway to a planned MAA submission for Vicineum in early 2021 with anticipated approval in early 2022

Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com (“Liberty” or the “Company”), a provider of high-quality cannabis, announced today that it is offering all holders of 12% Senior Secured Convertible Debentures (the “Debentureholders”) a 12-month extension to the original November 22, 2020 maturity date (the “Extension Option”) that were originally issued on November 22, 2017 (the “Debentures”).

Lygos, Inc., a vertically integrated provider of safe and sustainable specialty ingredients, today announced the launch of Lygos CBx, a Lygos company and new website focused on delivering a wide range of high-quality, pure and sustainable non-plant-based cannabinoids

Promotion follows the Company’s achievement of key manufacturing milestones to support upcoming clinical trials

KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced postponement of the Special Meeting of Stockholders that was originally scheduled to be held on Tuesday, October 27, 2020 at 8:00 a.m. ET (the “Special Meeting”).

In conjunction with Diabetes Awareness Month in November, the American Association of Clinical Endocrinology announced the launch of the ‘The Lowdown on Low Blood Sugar’ campaign to raise awareness of hypoglycemia, also known as low blood sugar, and help people at risk be prepared for a low blood sugar emergency.